Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01637753 : Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
PhaseN/A
AgesMin: 18 Years Max: 70 Years
Eligibility
Inclusion Criteria:

- Patients must be 18 to 70 years old, signed ICF;

- At least 4 weeks after previous chemotherapy (6 weeks since nitrosoureas);

- KPS ? 60;

- Unilateral, Supratentorial, solitary lesion and not crossing the midline(exclude
patients with little tumors near the resectable tumor even if investigators think
they are single lesions)

- No obvious important organ dysfunction: Blood routine: White blood cell (WBC) ?
4.0×109/L, Absolute neutrophil count (ANC)? 1.5×109/L, Platelets? 100×109/L,
Hemoglobin? 90 g/L; Hepatic function:Serum total bilirubin ?1.5 times upper limit of
laboratory normal; Aspartate aminotransferase (AST) and/or Alanine aminotransferase
(ALT)?2.5 times upper limit of laboratory normal; Renal function:Serum creatinine
?1.5 times upper limit of laboratory normal;

- Not Pregnant or lactating for women of childbearing potential.

Exclusion Criteria:

- Tumor located at ventricular system, Open ventricle tumor cavity postoperatively;

- Concomitant with other life-threatening diseases and with life expectancy ?3 months;

- Allergic to nitrosourea drugs;

- With history of intracranial radiotherapy or implant chemotherapy;

- With serious cardiac, pulmonary, hepatic and renal dysfunction, poor glycemic
control;

- Investigators thought unsuitable for enrollment.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01637753      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740